Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Adlai Nortye (NASDAQ: ANL) Targets Phase Ia Data for AN4035 in 2027

Adlai Nortye Group Ltd. (NASDAQ: ANL) has dosed the first patient in Australia in the global Phase I trial of AN4035, its CEACAM5-targeting antibody-drug conjugate. The U.S. Food and Drug Administration has also issued a “Study-May-Proceed” letter for the investigational new drug application, clearing …

Vinay Lochav | 09 September 2026

Zhihu (NYSE: ZH) Shareholders Must Approve Proposed AI Fund Investment

The cash commitment would be made through aWholly Owned Subsidiaryunder the fund’s capital-call arrangements.

Vinay Lochav | 09 September 2026

Zhihu Inc. (NYSE: ZH) Holds 1.55B Class A Shares Unchanged in August

Zhihu Inc. (NYSE: ZH) ended August with 1,550,000,000 authorised Class A ordinary shares (1.55 billion), unchanged during the month. The company also maintained USD 200,000 in total authorised or registeredShare Capitalacross its two WVR ordinary share classes. The monthly figures cover movements through 31 …

Vinay Lochav | 09 September 2026

ZIM Director Exercises Options for 13,459 Derivative Securities (NYSE: ZIM)

ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) director Meyer-Gloeckner Birger Johannes sold 1,531 shares at $28.50 per share on September 4, 2026, while exercising options for 13,459 derivative securities. After the transactions, the director held zero ZIM shares and zero derivative securities.

Vinay Lochav | 09 September 2026

Progyny, Inc. (NASDAQ: PGNY) Insider Forfeits 1,307 Shares at $26.29-$26.61

Progyny, Inc. (NASDAQ: PGNY) executive vice president and general counsel Swartz Allison forfeited 1,307 shares in two transactions. The reported prices ranged from $26.29 to $26.61 per share.

Vinay Lochav | 09 September 2026

Quantum Biopharma (NASDAQ: QNTM) Amends Report Tied to Registration No. 333-276264

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended an earlier regulatory report tied to registration number 333-276264, while leaving the rest of the initial report unchanged. The update is identified as Amendment No. 1.

Vinay Lochav | 09 September 2026

Quantum Biopharma (NASDAQ: QNTM) Amends Report With Amendment No. 1

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended its foreign private issuer report through Amendment No. 1, while stating that the initial report remains unchanged except for the matters covered by the amendment. The record carries reference 333-276264.

Vinay Lochav | 09 September 2026

Quantum Biopharma Amends Report Linked to 333-276264 (NASDAQ: QNTM)

Quantum Biopharma Ltd. (NASDAQ: QNTM) amended an earlier regulatory report linked to 333-276264, limiting the update to the changes identified in Amendment No. 1. The company says all other portions of the earlier report remain unchanged. The prior report continues as part of the …

Vinay Lochav | 09 September 2026

Richtech Robotics (NASDAQ: RR) Sets September 29 Annual Vote on Directors, Auditor

Richtech Robotics Inc. (NASDAQ: RR) will put two director seats and auditor ratification before stockholders at its September 29, 2026 annual meeting, with 39,934,846 Class A common shares outstanding on the record date. The meeting will take place at 10:00 a.m. Pacific time at …

Vinay Lochav | 09 September 2026

Snap Inc. (NYSE: SNAP) Sets Ajit Mohan Departure for December 31

Snap Inc. (NYSE: SNAP) Chief Business Officer Ajit Mohan plans to leave the company on December 31, 2026, to pursue other opportunities.

Vinay Lochav | 09 September 2026
Support

Hi! How can we help you today?

Loading…